[Ip-health] Lancet Commission on Essential Medicines Policies publishes 74 page report, endorses delinkage of R&D costs from drug prices | Knowledge Ecology International

Jamie Love james.love at keionline.org
Tue Nov 8 06:02:24 PST 2016

​The blog highlights some of the elements of the 74 page Lancet Commission
on Essential Medicines Policies report.


​This was the ​ ​KEI comment on the report:

The 22 members of the Lancet Commission on Essential Medicines Policies
have delivered a report rich in practical suggestions for expanding access
to treatments, and creating systems to ensure that there is robust
financing for R&D to address pressing health needs. The timing of this
report could not be better. The United State government and the WHO will
have new leadership in 2017, and this report can and should shape their
agendas. The Commission's impressive and knowledgeable members have
successfully blended the best inspirational values regarding fairness with
the concrete measures to achieve real results.

The Lancet Commission report provide more support for reforms that were
also addressed by the UN Secretary General High Level Panel and Access to
Medicines, including most importantly, to progressively delink R&D costs
from drug prices, both to improve the efficiency and efficacy of the system
of incentives for R&D, and to make access more fair.

James Love, Knowledge Ecology International​

More information about the Ip-health mailing list